Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Phase 2 Completed 272 enrolled AstraZeneca

NaParallel-groupOpen-labelTreatment

Summary

This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy.

Timeline

Start: 2016-12-22
Primary completion: 2020-12-03
Completion: 2020-12-03

Publications

Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS. Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib. Genome Med. 2024 Dec 18;16(1):145. doi: 10.1186/s13073-024-01413-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olaparib	Small molecule	300 mg	Oral

Indications

No indication recorded.